Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

BACKGROUND: We evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy. METHODS: In a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Hyun Cheol, Arkenau, Hendrik-Tobias, Lee, Jeeyun, Rha, Sun Young, Oh, Do-Youn, Wyrwicz, Lucjan, Kang, Yoon-Koo, Lee, Keun-Wook, Infante, Jeffrey R., Lee, Sung Sook, Kemeny, Margaret, Keilholz, Ulrich, Melichar, Bohuslav, Mita, Alain, Plummer, Ruth, Smith, Denis, Gelb, Arnold B., Xiong, Huiling, Hong, Janet, Chand, Vikram, Safran, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362598/
https://www.ncbi.nlm.nih.gov/pubmed/30717797
http://dx.doi.org/10.1186/s40425-019-0508-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362598/
https://www.ncbi.nlm.nih.gov/pubmed/30717797
http://dx.doi.org/10.1186/s40425-019-0508-1

Ejemplares similares